Opinion|Videos|May 19, 2025
The current treatment landscape of mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.
Advertisement
Episodes in this series
Treatment Options for mHSPC
Key Themes:
- Current 2025 guidelines recommend ADT with intensification.
- Multiple intensification options include abiraterone, darolutamide, and docetaxel.
- Key clinical trials include ARANOTE, ARASENS, and TITAN.
- All studies demonstrate survival benefit and delayed disease progression with intensification.
Key Points for Physicians:
- ADT monotherapy is no longer the standard of care.
- Multiple evidence-based intensification options exist.
- Selection can be tailored based on patient characteristics and preferences.
- All intensification approaches demonstrate benefit over ADT alone.
Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.
Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.
Advertisement
Related to this article
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5